The overall objective of this SPORE Immunodeficient Rodent laboratory Animal Core is to facilitate preclinical research in human lung cancer through the use of orthotopic cancer cell and tissue transplants (xenografts) in animal models. This shared resource will provide purchase, production breeding of and maintenance for specific pathogen-free, barrier- sustained, conventional, and severe-combined-immunodeficient (SCID) mice and athymic nude rats and mice for use by SPORE investigators in research projects in this program. This CORE will also provide gross and histopathology services, transgenic animal services, cancer will inoculation transfers, and harvests and animal model preparations for all program investigators using animal models. This CORE will maintain production colonies of pneumocystis carinii-free athymic nude rats and SCID mice in order to provide the necessary pulmonary disease-free animals required for these lung cancer studies. Animal studies supported by this CORE are focused on the primary SPORE Program objective which is to decrease incidence and mortality from lung cancer by discovery of cellular and molecular events involved in the progression of lung cancer and the translation of these discoveries into clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-04
Application #
5209218
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 435 publications